<DOC>
	<DOCNO>NCT00478387</DOCNO>
	<brief_summary>The purpose study determine immune response ovarian cancer patient remission , give flu vaccine . After receive flu vaccine , patient blood drawn 5 time 12 month study antibody response flu vaccine .</brief_summary>
	<brief_title>Ovarian Cancer Immune Response Flu Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must histologic diagnosis epithelial ovarian cancer primary peritoneal carcinoma . Time completion chemotherapy 6 month . If clinical evidence disease present diagnosis Stage III IV disease completion primary surgery chemotherapy , , clinical evidence disease present completion chemotherapy disease recurrence diagnose progressionfree interval least 2 year , patient initial stage . Prior malignancy ( except basal cell squamous cell skin cancer ) within past five year . Presence active CNS disease . Active bacterial , viral fungal infection . Chemotherapy , biologic therapy , radiation therapy &lt; 4 week prior study entry . History active autoimmunity immunosuppression . Use immunosuppressive drug within 4 week prior study entry . Patients may receive chemotherapy immunosuppressive medication discretion physician subsequent year influenza vaccination without exclusion study . Patients tumor low malignant potential ( borderline tumor ) eligible . Prior influenza vaccination current vaccine . History serious sensitivity egg , previous influenza vaccine . Pregnant breastfeeding subject .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Advanced Ovarian Primary Peritoneal Cancer Remission</keyword>
</DOC>